Publication | Closed Access

Targeting EGFR of triple-negative breast cancer enhances the therapeutic efficacy of paclitaxel- and cetuximab-conjugated nanodiamond nanocomposite

NanomedicineBreast OncologyEngineeringDrug TargetingCetuximab-conjugated Nanodiamond NanocompositeMedicinePolymer-drug ConjugateTherapeutic EfficacyBreast CancerTumor TargetingTriple-negative Breast CancerBiomedical EngineeringCancer TreatmentRadiation OncologyOncologyCell Biology